

Central Oncology Review

Specialized Institutional Review Board (IRB) Services for an Evolving Regulatory Landscape

Aligning the needs of the growing and increasingly complex field of oncology, Advarra's Central Oncology Review (COR) provides the robust human subject protections review that cancer researchers expect.

The COR Advantage



Expertise

COR's IRB roster includes distinguished oncologists and individuals from leading cancer centers, including ASCO-member oncologists as well as patient advocates. COR is experienced in reviewing specialized research protocols such as basket, umbrella, and targeted therapy trials utilizing just-in-time site activation.



Collaboration

COR acts as an extension of internal research programs, providing expertise and support to help institutions navigate the latest developments in oncology research, gene therapy review, and single IRB mandates. We have served as the IRB of record for 80% of all NCI-designated cancer centers.



Accelerated Startup

Advarra's IRB members understand the latest oncology methodologies and discoveries, which reduces unnecessary follow-up during the review process. COR helps researchers meet study activation milestones more quickly and speed patient accrual.



Transparency

COR maintains a transparent review process, offering access to documents and data in real time with the added ability to discuss issues with a dedicated support specialist. Always know the study's review status, anytime, anywhere.

IRB Experience in Oncology

- Antibody-drug conjugates
- Bladder/urinary tract cancer
- Blood and lymph cancers
- Breast cancer
- Cancer diagnostics
- Cervical cancer
- Chemotherapy
- Colon/colorectal cancer
- Endometrial cancer
- Gastric cancer
- Gene therapy
- Head and neck cancer
- Immunotherapy
- CAR-T cell therapy
- Liver cancer
- Lung cancer
- Ovarian cancer
- Pancreatic cancer
- Palliative care management
- Precision medicine (such as basket, umbrella, and targeted therapy trials)
- Prostate cancer
- Radiotherapy
- Renal cancer
- Sarcoma
- Skin cancer

Dedicated Support for Institutions

Advarra works with more institutions than any other central IRB, providing customized IRB review services for over 3,200 institutions, academic medical centers, hospitals, health systems, therapeutically focused research networks, and government entities. Each organization works with a single point of contact to ensure local requirements and other concerns are appropriately addressed.

IBC Services

Studies involving CAR-T cells, viral vectors, or genetically modified materials may require review by an institutional biosafety committee (IBC). Advarra's secure, cloud-based IBC submission platform is built from the same framework as its IRB platform, enabling seamless collaboration to provide concurrent IRB/IBC reviews, eliminate inconsistent determinations, and accelerate study startup.

For IBC review of COVID-19 research, Advarra averages less than 4-1/2 business days from receipt of a complete submission to IBC review.



Featuring OnCore, the premier enterprise CTMS solution for managing research operational data.

Ready to make your research altogether better?

Contact BusinessDevelopment@advarra.com to get started.



advarra.com